65,437 trials
CTEPH · Pulmonary Embolism · Early Diagnosis
Primary: To Identify the Accuracy of Routine CTPA for the Distinction of CTEPH From Acute PE. — 70; 70 Sensitivity
Coronary Artery Stenosis
Primary: Target Lesion Failure (TLF) — 5.4; 5.4 percentage of TLF
Substance Abuse
Primary: Recruitment Feasibility
Cerebral Palsy · Perinatal Stroke · Periventricular Leukomalacia
Primary: Change in Motor Evoked Potential Amplitude — 12.4; 81.7; -34.4 percent change
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer
Primary: Progression-free Survival — 2.9; 5.3 months — p=0.019
Coronary Artery Disease · Left Ventricular Dysfunction
Primary: Major Adverse Cardiac and Cerebrovascular Events — 23; 24 Participants
Emergency Service, Hospital · Motivational Interviewing · Advance Care Planning
Primary: Number of Patients Who Found the Intervention Acceptable and Provided Suggestions for Improvement — 48 Participants
Advanced Solid Tumors
Primary: Area Under the Free Plasma Concentration Time Curve From Zero to 24 Hours (AUC0-24) of Talazoparib on Day 22 — 111.8; 159.0; 123.6; NA nanogram*hour per milliliter
Healthy · Stress, Psychological
Primary: Change of the Heart Rate (HR) in Response to the Trier Social Stress Test (TSST) — 74.84; 74.34; 88.15; 86.69 bpm — p=0.757
Infant,Premature
Primary: Right Ventricular Energetic Efficiency Pre and Post Metoprolol — 15.5; 12.7 µJ/ml — p=0.004
Pancreatic Adenocarcinoma
Primary: Number of Participants With Relapse-free Survival — 3; 2 Participants
Sleep
Primary: Sleep Efficiency — 77.6; 76.8 percentage of time in bed sleeping
Tobacco Use Cessation
Primary: Number of Participants With Completion of at Least 2 Study Visits — 10; 7; 1 Participants
Prostatic Hyperplasia · Benign Prostatic Hyperplasia · Adenoma, Prostatic
Primary: International Prostate Symptom Score (IPSS) Change From Baseline — -0.4; -5.0; -13.1; -12.6 score on a scale
Pain, Post-operative
Primary: Opioid Consumption — 113.5; 147 milligrams oral morphine equivalent